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ABSTRACT
Background. In preclinical studies the heat shock protein 90 (Hsp90) inhibitor tanespimycin induces downregulation of checkpoint kinase 1 (Chk1) and other client proteins as well as increased sensitivity of acute leukemia cells to cytarabine. We now report a phase I and pharmacological study of the cytarabine/tanespimycin combination in adults with recurrent or refractory acute leukemia. Conclusions. Because exposure to potentially effective concentrations occurs only for a brief time in vivo, tanespimycin has little effect on resistance-mediating client proteins in relapsed leukemia at clinically tolerable doses and exhibits limited activity in combination with cytarabine
Design and
(clinicaltrials.gov identifier: NCT00098423).
INTRODUCTION
Heat shock protein 90 (Hsp90) is an abundant and ubiquitous molecular chaperone that helps many key cellular polypeptides assume or maintain their active conformations (1) (2) (3) . Extensive preclinical studies have examined this chaperone as a potential new drug target in hematological malignancies (3) (4) (5) (6) (7) . Among the >80 currently identified Hsp90 client proteins are several kinases involved in myeloid neoplasms, including Bcr/abl (8, 9) , Flt3 (4, 10, 11) , and c-Kit (12) , as well as the anti-apoptotic kinase Akt (13, 14) . When Hsp90 is inhibited, these polypeptides and other
Hsp90 clients fail to fold properly during synthesis and, as a consequence, decrease in abundance as mature molecules turn over (15, 16) . This client protein downregulation raises the possibility that Hsp90 inhibitors such as tanespimycin and alvespimycin might be used to simultaneously target multiple potential resistance mechanisms (1, 3, 6) . In addition, tanespimycin selectively inhibits growth of aneuploid cells (17) . Accordingly, there has been substantial interest in testing this class of agents in acute leukemia.
Although a recent phase I study of the Hsp90 inhibitor alvespimycin in patients with advanced myeloid leukemia revealed only a modest 18% CR rate (18) , the realization that pathways targeted by Hsp90 inhibitors contribute to drug resistance raises the question of whether Hsp90 inhibitors could be used as sensitizing agents in combination chemotherapy.
Previous studies have also provided the preclinical rationale for combining tanespimycin with a number of other agents, including imatinib (19) , Flt3 inhibitors (20) , histone deacetylase inhibitors (21, 22) , etoposide (23) and cytarabine (24) . The present work focused on the cytarabine/tanespimycin doublet because of its potential broad applicability to myeloid malignancies. Cytarabine triggers sequential activation of Ataxia Telangiectasia Mutated/Rad3-related (ATR) kinase and its substrate checkpoint kinase 1 (Chk1) ex vivo (24) (25) (26) , thereby activating the replication checkpoint (27) . Conversely, Chk1 downregulation by RNA interference or treatment with tanespimycin abrogates this checkpoint (28) and sensitizes cells to cytarabine in vitro (24) , suggesting that replication checkpoint signaling is protective.
We now report a phase I study of cytarabine and tanespimycin in patients with relapsed/refractory acute leukemia and accelerated phase (AP) or blast crisis (BC) CML. The goals of this study were to not only assess the toxicities and establish the maximum tolerated dose (MTD) of the cytarabine/tanespimycin combination, but also examine the effect of tanespimycin on levels of Hsp90 clients in leukemic blasts in situ. Acquisition scan, pulmonary function tests and baseline pulse oximetry were performed. The physical examination and chemistry tests were repeated at least twice weekly during each cycle.
DESIGN AND METHODS
Patient
CBCs were performed daily until neutrophils and platelets were >500/mm 3 and 20,000/mm 3 , respectively.
Dose, Schedule and Escalation Scheme. A cytarabine regimen previously employed for consolidation (29) was utilized because the cytarabine dose (400 mg/m 2 /d x 5 days) was higher than patients typically received as part of their prior induction therapy. Because tanespimycin induces a G1 and G2 arrest (24) , which could potentially inhibit the replication required for cytarabine-induced cytotoxicity (24, 30, 31) , tanespimycin was administered for the first time Response evaluation. Bone marrow aspirates and biopsies were obtained within 48 h prior to initiation of therapy, on day 10-15, and every 7-14 days thereafter until counts recovered. CR and PR were defined as previously reported (33), consistent with existing recommendations (34).
Pharmacokinetic Analysis. Blood samples were drawn on day 3 before tanespimycin infusion;
115 min into the 2-h infusion; and 5 min, 3 h, 9 h and 24 h after the end of infusion. Plasma concentrations of tanespimycin and its principal metabolite 17-aminogeldanamycin (17AG) were determined as described (32) . Tanespimycin and 17AG plasma concentration-time data were analyzed by non-compartmental methods using WINNONLIN version 4.1 (Pharsight Corp., Mountainview, CA). Buffy coat DNA was genotyped as described (32) for CYP3A5 polymorphisms, which are known to affect tanespimycin clearance.
Immunoblotting. Marrow mononuclear cells were isolated (35) before treatment, on day 3 prior to tanespimycin, and on day 4 at 22 ± 2 h after the start of tanespimycin (Fig. 1) . Whole cell lysates prepared in guanidine hydrochloride were processed for immunoblotting (35) , which was performed using antibodies identified previously (24, 32, 36) . Marrow mononuclear cells from pretreatment samples were also treated ex vivo as described (24) .
RESULTS
Patient characteristics. Twenty-six adult leukemia patients (Table 1 ) received 30 courses of cytarabine + tanespimycin at five dose levels ( Nonhematological toxicities (Table 3) . Consistent with the observed myelosuppression, neutropenic fever occurred in all patients and was treated with empiric antimicrobial regimens.
There were three infectious deaths, one at dose level 3 (on day 7 due to disseminated Candida tropicalis) and two at dose level 5 (one on day 9 with fungal pneumonia and one on day 19 with E. coli sepsis). A third patient at level 5 developed acute respiratory distress syndrome (ARDS) on day 7 leading to multi-organ failure and >2 weeks of mechanical ventilation before recovery.
Patients treated at dose level 5 were also noted by their physicians to appear sicker and less Pharmacokinetics. The pharmacokinetics of tanespimycin and its metabolite 17AG, which also 8 affects client protein stability (24), were evaluable for 20 patients (Table S1 ). Mean tanespimycin clearance was 17.8 ± 6.4 L/h/m 2 . The half-lives for tanespimycin and 17AG were 4.5 ± 2.7 hours and 6.1 ± 1.9 hours, respectively. Moreover, tanespimycin and 17AG peak plasma concentrations and AUCs increased with dose over the 150-350 mg/m 2 range.
Importantly, tanespimycin mean peak plasma concentrations were >3000 nM at all dose levels;
and 17AG mean peak plasma concentrations exceeded 1500 nM.
Because client protein downregulation is known to require extended tanespimycin exposure (16, 24) , we also examined the duration of tanespimycin and 17AG plasma concentrations above 300 nM, a concentration previously shown to induce substantial client protein downregulation after 24 h in leukemia cell lines in vitro (24) , and 1000 nM, a concentration commonly used in preclinical studies. The sum of the tanespimycin and 17AG
concentrations exceeded 300 nM for >10 h in all patients (Table 4 ). This sum exceeded 300 nM for >24 h in only three patients, none of whom had an obvious explanation based on cytochrome P450 polymorphisms. All three patients with prolonged drug exposure experienced severe adverse events, including an MI (dose level 2) and fatal sepsis (1 patient each at dose level 3 and dose level 5).
Hsp90 client protein expression.
Correlative studies were designed to determine whether treatment affects Hsp90 function in situ. Bone marrow aspirates harvested prior to therapy, on day 3 before tanespimycin, and on day 4 at 22 ± 2 h after tanespimycin ( Fig. 1) were blotted for several Hsp90 clients that are downregulated by tanespimycin in leukemia cell lines ( Fig. 2A and ref. 24) . Whenever possible, aliquots of pretreatment marrow were also exposed to cytarabine or tanespimycin ex vivo for comparison.
Based on preclinical results, decreased levels of the Hsp90 clients and increased levels of Hsp70 (due to transcription mediated by heat shock factor-1 (HSF-1) released from Hsp90-ref.
1) were anticipated on day 4. Contrary to this prediction, decreases of the Hsp90 clients ILK,
Akt, c-Raf and IGF1R were difficult to discern, although there were modest increases in Hsp70
( Fig. 2B-2D, in vivo) . Exposure of pretreatment blasts to tanespimycin for 24 h ex vivo confirmed that tanespimycin was able to downregulate Chk1, Akt and c-Raf at 300 and 1000 nM ( Fig. 2B and D ex vivo) , albeit less extensively than in AML lines ( Fig. 2A, lane 4) or samples of previously untreated AML (24) . In total, 17 sets of sequential samples were analyzed. Hsp70
showed a readily discernible increase between day 3 and day 4 in 10 of 12 (83%) samples that 9 yielded an Hsp70 signal. In contrast, only 3 of 13 (23%) and 1 of 13 (8%) day 4 samples had decreased c-Raf or ILK, respectively, relative to baseline, indicating that effects on client proteins in leukemic blasts in situ were modest at the tanespimycin exposures achieved clinically. Moreover, there was no apparent relationship between these changes and clinical response.
DISCUSSION
In the present study, we report the first results of a tanespimycin-containing combination in patients with relapsed/refractory acute leukemias and the first analysis of effects of these agents on Hsp90 clients in leukemia specimens in situ. Our results have potentially important implications for current efforts to modulate leukemia resistance mechanisms with Hsp90 inhibitors.
Several issues were considered in designing the present study. First, the trial built on an established cytarabine regimen with defined activity and toxicity (29) . Second, a cytarabine regimen that incorporates more than the usual 100-200 mg/m Among 22 AML patients, 1 CR and 2 PRs were observed, all in leukemias that relapsed soon after or were refractory to prior cytarabine-containing regimens. In addition, a CR was observed in a patient with primary refractory Ph + ALL; and two hematological PRs were observed in patients with AP-CML, for an overall response rate of 23%. Enthusiasm for this regimen, however, was tempered by the short duration of all but one response and the seriousness of the adverse events.
Correlative studies were performed to determine whether tanespimycin had the anticipated impact on Hsp90 clients. Comparison of samples harvested before and 22 ± 2 h after tanespimycin demonstrated discernible Chk1 decreases in 6 of 13 (46%) of cases. The magnitude of Chk1 downregulation, however, was relatively modest compared to tanespimycin-treated AML cell lines ( Fig. 2A and refs. 24, 28 ). Moreover, it was unclear that Chk1 downregulation reflected client protein degradation, as the Hsp90 client proteins c-Raf and ILK were downregulated in only 1 and 3 of 13 serial samples, respectively, on day 4 ( Fig. 2B-D ). An equally plausible explanation is that Chk1, which is expressed in a cell cycle-dependent manner (38) , decreased due to tanespimycin-induced changes in cell cycle progression (24) .
A number of prior studies have examined Hsp70 upregulation, which reflects increased activity of the transcription factor HSF-1 after release from Hsp90 (1), as a marker of tanespimycin action (18, 32, 39) . It is important to emphasize that Hsp70 upregulation results in resistance to Hsp90 inhibitors, not sensitization (40, 41) . In our study Hsp70 was upregulated after tanespimycin administration in blasts from 83% of patients. However, this Hsp70 upregulation sometimes occurred before tanespimycin administration (Day 3, Figs. 2B and 2D), possibly reflecting cytarabine-induced stress. Moreover, Hsp70 upregulation did not predict client protein downregulation. In preclinical studies published after completion of our work, response to Hsp90 inhibitors in xenografts correlated best with prolonged Hsp90 active site occupancy, which in turn correlated with Hsp90 client downregulation (16) . Accordingly, some marker other than Hsp70 upregulation might be needed to measure prolonged Hsp90 inhibition and sensitization in future combination studies.
Analysis of tanespimycin pharmacokinetics (Tables S1 and 4 ) provided a potential explanation for the limited downregulation of client proteins. The clearance of tanespimycin and 17AG in these leukemia patients (Table S1 ) was similar to that reported in earlier solid tumor trials (32, 39) . At the MTD, tanespimycin + 17AG exceeded 1000 nM, a concentration that induces substantial client protein downregulation in some samples after 24 h (Fig. 2B ), for only 5 h. In contrast, our previous studies demonstrated that a 6 h tanespimycin incubation is not sufficient to induce client protein downregulation in vitro (24) . Even though 350 mg/m 2 tanespimycin resulted in more prolonged exposure to potentially effective concentrations of tanespimycin + 17AG (Table 4) , this dose was not tolerable in combination with cytarabine.
Accordingly, it appears that a single 2-hour tanespimycin infusion at tolerable doses might not
give sufficient exposure to induce substantial client protein downregulation in leukemic blasts in vivo. Examination of the pharmacokinetic data in Table S1 and a graph of pooled mean plasmaconcentration data for each dose level suggests that levels of tranespimycin + 17AG above 300 nM could be sustained in most patients for >24 h by administration of 150 mg/m 2 tanespimycin every 12 hours x 2 doses on day 3 and again on day 6. Based on the adverse events observed in the present study, however, it is unclear whether such a schedule would be tolerable.
In summary, the present study has defined the MTD of the cytarabine + tanespimycin regimen as cytarabine 400 mg/m 2 /d x 5 days and tanespimycin 300 mg/m 2 /dose on days 3 and 6.
Despite the ability of tanespimycin to modulate multiple resistance mechanisms in vitro, disruption of these same pathways in leukemic cells in situ was difficult to demonstrate, likely reflecting drug exposure that was insufficient to downregulate client proteins in leukemic blasts.
It is possible that alternative Hsp90 inhibitors, especially those lacking a geldanamycin backbone (42) , might exhibit a wider therapeutic index in this setting. Alternatively, in view of the recent development of highly effective and selective inhibitors of clients such as checkpoint kinases (43) (44) (45) , Akt (42, 46, 47) and IGFR (47) , it will also be interesting to see whether these agents offer any benefit when combined with cytarabine in AML patients.
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